Cited by 188Pharmacovigilance and Adverse Drug ReactionsInfluenza Virus Research StudiesData-Driven Disease Surveillance

The DOI matches its Crossref record; 60 of the 64 references it cites were found in a registry or an index.

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Vellozzi, Claudia, Burwen, Dale R., Dobardzic, Azra, Ball, Robert, Walton, Kimp, Haber, Penina·2009·Vaccine

DOI 10.1016/j.vaccine.2009.01.125

Open this paper in CoChat — free account

Abstract

In preparation for pandemic vaccine safety monitoring, we assessed adverse events reported to the Vaccine Adverse Event Reporting System following receipt of trivalent inactivated influenza vaccines among adults from 1990 through 2005. We calculated reporting rates for nonserious, serious, and neurological adverse events. We reviewed reports of recurrent events and deaths, as well as reports identified through advanced signal detection. The most frequently reported events were local reactions and systemic symptoms. Guillain-Barré syndrome was the most frequently reported serious event (0.70 reports per million vaccinations). Adverse event reporting rates have been reasonably constant over time. No new safety concerns emerged after our review of 15 years of post-licensure surveillance data. These findings provide useful information if pandemic vaccine is rapidly distributed and pre-licensure data are limited.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2009.01.125

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Fiore, A. E., Shay, D. K., Broder, K. R., Iskander, J. K., Uyeki, T. M., Mootrey, G., Bresee, J. S., & Cox, N. S. (2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,006
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
Evans, S., WALLER, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,808
Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System
DuMouchel, W. (1999) · The American Statistician · doi:10.1080/00031305.1999.10474456 · Cited by 883
Proposed diagnostic criteria and nosology of acute transverse myelitis
Transverse Myelitis Consortium Working Group* (2002) · Neurology · doi:10.1212/wnl.59.4.499 · Cited by 806
GUILLAIN-BARRE SYNDROME FOLLOWING VACCINATION IN THE NATIONAL INFLUENZA IMMUNIZATION PROGRAM, UNITED STATES, 1976–19771
Schonberger, L. B., Bregman, D. J., SULLIVAN-BOLYAI, J. Z., Keenlyside, R. A., Ziegler, D. W., RETAILLIAU, H. F., EDDINS, D. L., & Bryan, J. A. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112795 · Cited by 784
Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA??s Spontaneous Reports Database
Szarfman, A., Machado, S. G., & Neill, R. T. O. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00001 · Cited by 712
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055778 · Cited by 698
Proposed diagnostic criteria and nosology of acute transverse myelitis
Román, G. C. (2003) · Neurology · doi:10.1212/wnl.60.4.730 · Cited by 531
The Guillain–Barré Syndrome and the 1992–1993 and 1993–1994 Influenza Vaccines
Lasky, T., Terracciano, G. J., Magder, L. S., Koski, C. L., Ballesteros, M., Nash, D., Clark, S., Haber, P., Stolley, P. D., Schonberger, L. B., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812173392501 · Cited by 501
Self-citation
The Vaccine Adverse Event Reporting System (VAERS)
CHEN, R., RASTOGI, S., MULLEN, J., HAYES, S., COCHI, S., DONLON, J., & WASSILAK, S. (1994) · Vaccine · doi:10.1016/0264-410x(94)90315-8 · Cited by 498

Show all 64 references

Research works printed but not linked: 1

King, 2001, National Advisory Committee on Immunization (NACI), Supplementary statement on influenza vaccination: continued use of Fluviral influenza vaccine in the 2000–2001 influenza season, Can Commun Dis Rep, 27, 1

Sorted by citations

Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
Fiore, A. E., Uyeki, T. M., Broder, K. R., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M., Shay, D. K., Bresee, J., et al. (2009) · PubMed · Cited by 1,964
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,640
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011
(2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03793.x · Cited by 957
Prevention and Control of Seasonal Influenza with Vaccines
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. B., & Bresee, J. (2016) · MMWR Recommendations and Reports · doi:10.15585/mmwr.rr6505a1 · Cited by 602
Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014.
Grohskopf, L. A., Shay, D. K., Shimabukuro, T. T., Sokolow, L. Z., Keitel, W. A., Bresee, J., & Cox, N. J. (2013) · PubMed · Cited by 471
Risk of anaphylaxis after vaccination in children and adults.
McNeil, M. M., Weintraub, E. S., Duffy, J., Sukumaran, L., Jacobsen, S. J., Klein, N. P., Hambidge, S. J., Lee, G. M., Jackson, L. A., Irving, S. A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.048 · Cited by 381
Guillain-Barré syndrome after exposure to influenza virus
Lehmann, H. C., Hartung, H., Kieseier, B. C., & Hughes, R. A. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70140-7 · Cited by 199
Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009
Moro, P. L., Broder, K. R., Zheteyeva, Y. A., Walton, K., Rohan, P., Sutherland, A., Guh, A. Y., Haber, P., Destefano, F. R., & Vellozzi, C. J. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.08.050 · Cited by 165
Self-citation
COVID-19: Progress in diagnostics, therapy and vaccination
Liu, X., Liu, C., Liu, G., Luo, W., & Xia, N. (2020) · Theranostics · doi:10.7150/thno.47987 · Cited by 159
A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia
Fadlyana, E., Rusmil, K., Tarigan, R., Rahmadi, A. R., Prodjosoewojo, S., Sofiatin, Y., Khrisna, C. V., Sari, R. M., Setyaningsih, L., Surachman, F., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.09.052 · Cited by 144
Inactivated influenza vaccines
Fiore, A. E., Bridges, C. B., Katz, J. M., & Cox, N. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00026-4 · Cited by 135
Near Real-Time Surveillance for Influenza Vaccine Safety: Proof-of-Concept in the Vaccine Safety Datalink Project
Greene, S. K., Kulldorff, M., Lewis, E. M., Li, R., Yin, R., Weintraub, E., FIREMAN, B. H., Lieu, T. A., Nordin, J. D., Glanz, J. M., et al. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp345 · Cited by 132
Guillain-Barre syndrome and influenza vaccines: a meta-analysis.
Martín Arias, L. H., Sanz, R., Sáinz, M., Treceño, C., & Carvajal, A. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.013 · Cited by 132
Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010
Vellozzi, C. J., Broder, K. R., Haber, P., Guh, A. Y., Nguyen, M., Cano, M. V., Lewis, P., McNeil, M. M., Bryant, M., Singleton, J. A., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.09.021 · Cited by 125
Self-citation
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
Tiboni, M., Casettari, L., & Illum, L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120686 · Cited by 116
Risk of Guillain-Barre syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study.
Kwong, J. C., Vasa, P. P., Campitelli, M. A., Hawken, S., Wilson, K., Rosella, L. C., Stukel, T. A., Crowcroft, N. S., McGeer, A. J., Zinman, L., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70104-x · Cited by 115
Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System
Moro, P. L., Broder, K. R., Zheteyeva, Y. A., Revzina, N., Tepper, N. K., Kissin, D. M., Barash, F., Arana, J., Brantley, M. D., Ding, H., et al. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.047 · Cited by 109
Self-citation
“Prepandemic” Immunization for Novel Influenza Viruses, “Swine Flu” Vaccine, Guillain‐Barré Syndrome, and the Detection of Rare Severe Adverse Events
Evans, D., Cauchemez, S., & Hayden, F. G. (2009) · The Journal of Infectious Diseases · doi:10.1086/603560 · Cited by 91
Deaths following vaccination: What does the evidence show?
Miller, E. R., Moro, P. L., Cano, M. V., & Shimabukuro, T. T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.023 · Cited by 88
The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the vaccine and why?
Raude, J., Caille-Brillet, A.-L., & Setbon, M. (2010) · PLoS Currents · doi:10.1371/currents.rrn1188 · Cited by 72
The Saudi Thoracic Society guidelines for influenza vaccinations
Zeitouni, M. O., Barrak, A. A., Al-Moamary, M. S., Alharbi, N., Idrees, M., Shimemeri, A. A., & Al-Hajjaj, M. (2015) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.167065 · Cited by 66
A review of the changes to the licensing of influenza vaccines in Europe
Wijnans, L., & Voordouw, B. C. G. (2015) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12351 · Cited by 65
Technical guidelines for the application of seasonal influenza vaccine in China (2014–2015)
Feng, S., Yang, P., Zhang, T., Yang, J., Fu, C., Qin, Y., Zhang, Y., Ma, C., Liu, Z., Wang, Q., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1027470 · Cited by 63
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
Ashraf, M. U., Kim, Y., Kumar, S., Seo, D., Ashraf, M., & Bae, Y. (2021) · Vaccines · doi:10.3390/vaccines9020171 · Cited by 62
AE-GPT: Using Large Language Models to extract adverse events from surveillance reports-A use case with influenza vaccine adverse events
Li, Y., Li, J., He, J., & Tao, C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300919 · Cited by 67
Ontology-Based Combinatorial Comparative Analysis of Adverse Events Associated with Killed and Live Influenza Vaccines
Sarntivijai, S., Xiang, Z., Shedden, K., Markel, H., Omenn, G. S., Athey, B. D., & He, Y. O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049941 · Cited by 54
Febrile seizures after 2010–2011 influenza vaccine in young children, United States: A vaccine safety signal from the vaccine adverse event reporting system
Leroy, Z. C., Broder, K. R., Menschik, D., Shimabukuro, T. T., & Martin, D. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.042 · Cited by 51
Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations
Banzhoff, A., Haertel, S., & Praus, M. (2011) · Human Vaccines · doi:10.4161/hv.7.5.14821 · Cited by 50
On the road to ending the COVID-19 pandemic: Are we there yet?
Case, J. B., Winkler, E. S., Errico, J. M., & Diamond, M. (2021) · Virology · doi:10.1016/j.virol.2021.02.003 · Cited by 47
Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation
Jeffs, L., Nitschke, J., Tervaert, J. W. C., Peh, C. A., & Hurtado, P. R. (2015) · Clinical Rheumatology · doi:10.1007/s10067-015-3073-0 · Cited by 50
Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms
Jafari, A., Pouya, F. D., Niknam, Z., Abdollahpour‐Alitappeh, M., Rezaei–Tavirani, M., & Rasmi, Y. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07132-7 · Cited by 52
Immunization-Safety Monitoring Systems for the 2009 H1N1 Monovalent Influenza Vaccination Program
Salmon, D. A., Akhtar, A. Z., Mergler, M. J., Vannice, K., Izurieta, H. S., Ball, R., Lee, G. M., Vellozzi, C. J., Garman, P. M., Cunningham, F. E., et al. (2011) · PEDIATRICS · doi:10.1542/peds.2010-1722l · Cited by 47
Self-citation
Administering influenza vaccine to egg-allergic persons
Kelso, J. M. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.933079 · Cited by 39
Determinants of influenza vaccination uptake in pregnancy: a large single-Centre cohort study
Bartolo, S., Deliege, E., Mancel, O., Dufour, P., Vanderstichèle, S., Roumilhac, M., Hammou, Y., Carpentier, S., Dessein, R., Subtil, D., et al. (2019) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-019-2628-5 · Cited by 38
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013−May 31, 2015
Haber, P., Moro, P. L., Lewis, P., Woo, E. J., Jankosky, C., & Cano, M. V. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.048 · Cited by 37
Self-citation
Should healthcare workers have the swine flu vaccine?
Jordan, R. E., & Hayward, A. C. (2009) · BMJ · doi:10.1136/bmj.b3398 · Cited by 37
Acute disseminated encephalomyelitis following influenza vaccination
Shoamanesh, A., & Traboulsee, A. L. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.103 · Cited by 35
Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy
Myers, E. R., Misurski, D. A., & Swamy, G. K. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.04.009 · Cited by 34
The importance of influenza prevention for public health
Carrillo-Santisteve, P., Ciancio, B. C., Nicoll, A., & Lopalco, P. L. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.19066 · Cited by 35
Extracting postmarketing adverse events from safety reports in the vaccine adverse event reporting system (VAERS) using deep learning
Du, J., Xiang, Y., Sankaranarayanapillai, M., Zhang, M., Wang, J., Si, Y., Pham, H. A., Xu, H., Chen, Y., & Tao, C. (2021) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocab014 · Cited by 36
The "urban myth" of the association between neurological disorders and vaccinations
Gasparini, R., Panatto, D., Lai, P. L., & Amicizia, D. (2015) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2015.56.1.467 · Cited by 34
Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated?
Maiese, A., Baronti, A., Manetti, A. C., Paolo, M. D., Turillazzi, E., Frati, P., & Fineschi, V. (2022) · Vaccines · doi:10.3390/vaccines10020308 · Cited by 33
Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan
Huang, W., Chen, W., Yang, H.-W., Chen, W., Chao, Y.-N., Huang, Y.-W., Chuang, J.-H., & Kuo, H. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.069 · Cited by 33
From the patient perspective: The economic value of seasonal and H1N1 influenza vaccination
Lee, B. Y., Bacon, K. M., Donohue, J. M., Wiringa, A. E., Bailey, R. R., & Zimmerman, R. K. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.078 · Cited by 33
First French Experience of ADR Reporting by Patients After a Mass Immunization Campaign with Influenza A (H1N1) Pandemic Vaccines
Durrieu, G., Palmaro, A., Pourcel, L., Caillet, C., Faucher, A., Jacquet, A., Ouaret, S., Pérault‐Pochat, M. C., Kreft-Jaïs, C., Castot, A., et al. (2012) · Drug Safety · doi:10.1007/bf03261980 · Cited by 32
Administration of influenza vaccines to patients with egg allergy
Kelso, J. M. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.013 · Cited by 31
COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
Al-Jighefee, H. T., Najjar, H., Ahmed, M. N., Qush, A., Awwad, S., & Kamareddine, L. (2021) · Vaccines · doi:10.3390/vaccines9101196 · Cited by 29
Influence of Granulocyte-Macrophage Colony-Stimulating Factor or Influenza Vaccination on HLA-DR, Infection and Delirium Days in Immunosuppressed Surgical Patients: Double Blind, Randomised Controlled Trial
Spies, C., Luetz, A., Lachmann, G., Renius, M., von Haefen, C., Wernecke, K., Bahra, M., Schiemann, A., Paupers, M., & Meisel, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144003 · Cited by 26
A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries
Haugh, M. C., Gresset-Bourgeois, V., Macabeo, B., Woods, A., & Samson, S. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1324302 · Cited by 26
Utility of Healthcare System-Based Interventions in Improving the Uptake of Influenza Vaccination in Healthcare Workers at Long-Term Care Facilities: A Systematic Review
Bechini, A., Lorini, C., Zanobini, P., Tacconi, F. M., Boccalini, S., Grazzini, M., Bonanni, P., & Bonaccorsi, G. (2020) · Vaccines · doi:10.3390/vaccines8020165 · Cited by 29
Overview of Nonhuman Primate Models of SARS-CoV-2 Infection
Trichel, A. M. (2021) · Comparative Medicine · doi:10.30802/aalas-cm-20-000119 · Cited by 28
Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance
Kurz, X., Domergue, F., Slattery, J., Segec, A., Szmigiel, A., & Hidalgo‐Simon, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.005 · Cited by 26
Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990–2013
Miller, E. R., Moro, P. L., Cano, M. V., Lewis, P., Bryant-Genevier, M. G., & Shimabukuro, T. T. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.021 · Cited by 26
Immunotherapeutics for Covid-19 and post vaccination surveillance
Kumar, N. S. S., Chintagunta, A. D., Kumar, S., Roy, S., & Kumar, M. (2020) · 3 Biotech · doi:10.1007/s13205-020-02522-9 · Cited by 25
The PREGVAXGRIP Study: a Cohort Study to Assess Foetal and Neonatal Consequences of In Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza
Chavant, F., Ingrand, I., Jonville‐Béra, A. ‐., Plazanet, C., Gras‐Champel, V., Lagarce, L., Zénut, M., Dautriche, A., Logerot, S., Auffret, M., et al. (2013) · Drug Safety · doi:10.1007/s40264-013-0030-1 · Cited by 25
Influenza vaccination: key facts for general practitioners in Europe—a synthesis by European experts based on national guidelines and best practices in the United Kingdom and the Netherlands
Kassianos, G. C., Blank, P. R., Falup‐Pecurariu, O., Kuchar, E. P., Kynčl, J., de Lejarazu, R. O., Nitsch-Osuch, A. S., & van Essen, G. A. (2016) · Drugs in Context · doi:10.7573/dic.212293 · Cited by 25
Inactivated Influenza Vaccines
Bresee, J., Fry, A. M., Sambhara, S. R., & Cox, N. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00031-6 · Cited by 24
An update on influenza vaccination in patients with egg allergy
Gruenberg, D. A., & Shaker, M. (2011) · Current opinion in pediatrics · doi:10.1097/mop.0b013e32834ac7a3 · Cited by 17
Mandatory Influenza Vaccination for Health Care Workers as the New Standard of Care: A Matter of Patient Safety and Nonmaleficent Practice
Cortes-Penfield, N. W. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301514 · Cited by 23
Safety of Pandemic (H1N1) 2009 Monovalent Vaccines in Taiwan: A Self-Controlled Case Series Study
Huang, W., Yang, H.-W., Liao, T.-L., Wu, W.-J., Yang, S.-E., Chih, Y.-C., & Chuang, J.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058827 · Cited by 23
Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16
Bricout, H., Chabanon, A.-L., Souverain, A., Sadorge, C., Vesikari, T., & Caroe, T. D. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.18.30527 · Cited by 23
Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea
Park, Y.-S., Lee, K., Kim, S. W., Kim, K. M., & Suh, B. C. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.7.1154 · Cited by 22
Evaluation of Immunoreactivity and Protection Efficacy of Seneca Valley Virus Inactivated Vaccine in Finishing Pigs Based on Screening of Inactivated Agents and Adjuvants
Liu, W., Li, X., Zhang, H., Hao, G., Shang, X., Wang, H., Chen, H., & Qian, P. (2022) · Vaccines · doi:10.3390/vaccines10040631 · Cited by 22
Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003–2010
Choe, Y. J., Cho, H., Kim, S. N., Bae, G., & Lee, J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.129 · Cited by 22
Recommendations for influenza and Streptococcus pneumoniae vaccination in elderly people in China
Chen, Q., Wang, L., Xie, M., Li, X., & Recommendations for Influenza, S. P. V. I. E. P. I. C. W. G. (2020) · Aging Medicine · doi:10.1002/agm2.12102 · Cited by 21
Influenza vaccine-induced interstitial lung disease
Watanabe, S., Waseda, Y., Takato, H., Inuzuka, K., 片山, 伸., Kasahara, K., & Fujimura, M. (2013) · European Respiratory Journal · doi:10.1183/09031936.00146912 · Cited by 21
Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: The importance of routine active safety surveillance
Petousis‐Harris, H., Poole, T., Turner, N. M., & Reynolds, G. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.052 · Cited by 21
Adverse Events following Immunization (AEFI) with the Novel Influenza A (H1N1) 2009 Vaccine: Findings from the National Registry of All Vaccine Recipients and AEFI and the Passive Surveillance System in South Korea
Kim, J.-H., Cho, H.-Y., Hennessey, K. A., Lee, H. J., Bae, G. R., & Kim, H. C. (2012) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.65.99 · Cited by 21
Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
Kyei-Barffour, I., Akwetey, S. A., Aninagyei, E., Ghartey‐Kwansah, G., & Acheampong, D. O. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112282 · Cited by 21
Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax;a Systematic Review.
Dadras, O., Mehraeen, E., Karimi, A., Tantuoyir, M. M., Afzalian, A., Nazarian, N., Mojdeganlou, H., Mirzapour, P., Shamsabadi, A., Dashti, M., et al. (2022) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v10i1.1585 · Cited by 19
Should expectant mothers be vaccinated against flu? A safety review
Loubet, P., Kernéis, S., Anselem, O., Tsatsaris, V., Goffinet, F., & Launay, O. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.977252 · Cited by 21
Comparison of response rates on invitation mode of a web-based survey on influenza vaccine adverse events among healthcare workers: a pilot study
Tai, X., Smith, A. M., McGeer, A., Dubé, È., Holness, D. L., Katz, K. C., Hall, L. M., McNeil, S., Powis, J. E., & Coleman, B. L. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0524-8 · Cited by 20
Severe Childhood Respiratory Viral Infections
Hon, K. E., & Leung, A. K. C. (2009) · Advances in Pediatrics · doi:10.1016/j.yapd.2009.08.019 · Cited by 20
New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain
Poland, G. A., Fleming, D., Treanor, J. J., Maraskovsky, E., Luke, T. C., Ball, E. M. A., & Poland, C. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.033 · Cited by 19
Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >= 60 years of age in Lao People’s Democratic Republic
Ortega‐Sanchez, I. R., Mott, J. A., Kittikraisak, W., Khanthamaly, V., McCarron, M., Keokhonenang, S., Ounaphom, P., Pathammavong, C., Phounphenghack, K., Sayamoungkhoun, P., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.011 · Cited by 19
Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients
Tartof, S. Y., Qian, L., Rieg, G. K., Yu, K. C., Sy, L. S., Tseng, H. F., Hechter, R. C., & Jacobsen, S. J. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1667 · Cited by 19
No evidence of a link between influenza vaccines and Guillain–Barre syndrome–associated antiganglioside antibodies
Wang, J., Boltz, D. A., McElhaney, J. E., McCullers, J. A., Webby, R. J., & Webster, R. G. (2011) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2011.00294.x · Cited by 18
A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice
Qiao, L., Chen, M., Li, S., Hu, J., Gong, C., Zhang, Z., & Cao, X. (2021) · Biomaterials Science · doi:10.1039/d1bm01060c · Cited by 19
Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
Feng, Y., Chen, J., Yao, T., Chang, Y., Li, X., Xing, R., Li, H., Xie, R., Zhang, X., Wei, Z., et al. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00924-2 · Cited by 17
Cost-Benefit Analysis of In-Hospital Influenza Vaccination of Postpartum Women
Ding, Y., Zangwill, K. M., Hay, J. W., Allred, N. J., & Yeh, S. H. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318242af27 · Cited by 16
Multipolymer microsphere delivery of SARS-CoV-2 antigens
Shahjin, F., Patel, M., Machhi, J., Cohen, J. D., Nayan, M. U., Yeapuri, P., Zhang, C., Waight, E. M., Hasan, M., Abdelmoaty, M. M., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.043 · Cited by 15
Modelling the risk-benefit impact of H1N1 influenza vaccines
Phillips, L. D., Fasolo, B., Zafiropoulous, N., Eichler, H. G., Ehmann, F., Jekerle, V., Kramarz, P., Nicoll, A., & Lönngren, T. (2013) · European Journal of Public Health · doi:10.1093/eurpub/ckt006 · Cited by 16
Postlicensure Safety Surveillance for High-Dose Trivalent Inactivated Influenza Vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010
Moro, P. L., Arana, J. S. V., Cano, M. V., Menschik, D., Yue, X., Lewis, P., Haber, P., Martin, D., & Broder, K. R. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis256 · Cited by 16
Self-citation
Pandemic influenza vaccination: Will the health care system take its own medicine?
Ferguson, C. D., Ferguson, T. E., Golledge, J., & McBride, W. J. H. (2010) · Australian Journal of Rural Health · doi:10.1111/j.1440-1584.2010.01148.x · Cited by 15
Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children
Muhammad, R. D., Haber, P., Broder, K. R., Leroy, Z. C., Ball, R., Braun, M. M., Davis, R. L., & McMahon, A. W. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181ff9795 · Cited by 15
Self-citation
Guillain-Barré-Syndrom nach Exposition mit Influenza
Hartung, H., Keller‐Stanislawski, B., Hughes, R. A., & Lehmann, H. C. (2012) · Der Nervenarzt · doi:10.1007/s00115-012-3479-8 · Cited by 15
Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study
Simpson, C. R., Lone, N., Kavanagh, K., Robertson, C., McMenamin, J., von Wissmann, B., Vasileiou, E., Butler, C., Ritchie, L. D., Gunson, R. N., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014200 · Cited by 15
Frequently asked questions on seven rare adverse events following immunization
D’Alò, G. L., Zorzoli, E., Capanna, A., Gervasi, G., Terracciano, E., Zaratti, L., & Franco, E. (2016) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2017.58.1.659 · Cited by 14
Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009/10
Kraigher, A., & Učakar, V. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.05.066 · Cited by 14
Swine Influenza A (H1N1 Virus): A pandemic disease
Gangurde, H., Borkar, V., Khandare, R., Gulecha, V., Mahajan, M., & Mundada, A. S. (2011) · Systematic Reviews in Pharmacy · doi:10.4103/0975-8453.86300 · Cited by 14
Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season
Chabanon, A.-L., Bricout, H., Ballandras, C., Souverain, A., Caroe, T. D., & BUTLER, K. M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1405882 · Cited by 13
Analysis of Individual Differences in Vaccine Pharmacovigilance Using VAERS Data and MedDRA System Organ Classes: A Use Case Study With Trivalent Influenza Vaccine
Du, J., Cai, Y., Chen, Y., He, Y. O., & Tao, C. (2017) · Biomedical Informatics Insights · doi:10.1177/1178222617700627 · Cited by 13
Prediction and detection of side effects severity following COVID-19 and influenza vaccinations: utilizing smartwatches and smartphones
Levi, Y., Brandeau, M. L., Shmueli, E., & Yamin, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-56561-w · Cited by 14
Trivalent influenza vaccine adverse symptoms analysis based on MedDRA terminology using VAERS data in 2011
Du, J., Cai, Y., Chen, Y., & Tao, C. (2016) · Journal of Biomedical Semantics · doi:10.1186/s13326-016-0056-2 · Cited by 12
Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia
Lara, C., Graeve, D. D., & Franco, F. (2018) · Value in Health Regional Issues · doi:10.1016/j.vhri.2018.01.001 · Cited by 11
Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization
Fumagalli, M. J., de Castro-Jorge, L. A., Fraga‐Silva, T. F. D. C., de Azevedo, P. O., Capato, C. F., Rattis, B. A. D. C., Hojo-Souza, N. S., Floriano, V. G., de Castro, J. T., Ramos, S. G., et al. (2021) · Viruses · doi:10.3390/v13122440 · Cited by 9
Introducing seasonal influenza vaccine in low‐income countries: an adverse events following immunization survey in the Lao People's Democratic Republic
Phengxay, M., Mirza, S. A., Reyburn, R., Xeuatvongsa, A., Winter, C. H., Lewis, H. C., Olsen, S. J., Tsuyuoka, R., Khanthamaly, V., Palomeque, F. S., et al. (2015) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12299 · Cited by 11
Analysis of COVID-19 vaccine adverse event using language model and unsupervised machine learning
Cheon, S., Methiyothin, T., & Ahn, I. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282119 · Cited by 10

Authors: Vellozzi, C., Burwen, D. R., Dobardzic, A., Ball, R., Walton, K., & Haber, P.
Affiliations: Centers for Disease Control and Prevention (US)
Center for Biologics Evaluation and Research (US)
Corresponding author: Vellozzi, Claudia
ORCID: Ball, Robert
Venue: Vaccine
Publisher: Elsevier BV
Published: 2009-03
Volume: 27
Issue: 15
Pages: 2114-2120
ISSN: 0264-410X (ISSN-L)
DOI: 10.1016/j.vaccine.2009.01.125
OpenAlex: W2008361529
Cited by: 188
References: 64
Citations by year: 2025: 1 · 2024: 5 · 2023: 7 · 2022: 16 · 2021: 24 · 2020: 12 · 2019: 5 · 2018: 11 · 2017: 11 · 2016: 9 · 2015: 14 · 2014: 7 · 2013: 11 · 2012: 17
FWCI: 26.57
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Vaccine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Health Sciences › Medicine › Epidemiology › Data-Driven Disease Surveillance
Keywords: trivalent inactivated influenza vaccine, vaccine safety, adverse events, VAERS, post-licensure surveillance, pandemic influenza vaccine, Guillain-Barré syndrome, neurological adverse events, local reactions, signal detection, adults
MeSH terms: Adult, Female, Humans, Influenza, Human, Influenza Vaccines, Male, Middle Aged, United States, Adverse Drug Reaction Reporting Systems, Guillain-Barre Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks